Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Canelas Vng – page 16

661 clinical trials in Canelas Vng, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Canelas Vng at a glance
661
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

661 trials in Canelas Vng

Open in trial search

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Study on Pembrolizumab with Chemotherapy for Early-Stage Triple-Negative Breast Cancer in Patients with High TILs

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Champalimaud Clinical Centre

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Canelas Vng

What the registry says about research in the country

01 Cardiovascular Research

Clinical investigations focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease, exploring innovative therapeutic approaches for this complex patient population.

  • Cardiovascular Outcomes
  • Inflammation Markers
  • Dialysis Patient Care

The research aims to assess treatment effectiveness through monitoring C-reactive protein levels in dialysis patients, potentially leading to improved cardiovascular outcomes in this high-risk group.

02 Nephrology Studies

Specialized research targeting patients with end-stage kidney disease undergoing maintenance dialysis, evaluating novel therapeutic interventions to address cardiovascular complications.

  • Renal Disease Management
  • Dialysis Therapy
  • Cardiovascular Risk

These trials explore intravenous treatments aimed at reducing inflammation markers and improving overall outcomes in dialysis patients.

03 Inflammatory Biomarkers

Investigation of inflammatory markers in cardiovascular disease, specifically focusing on high-sensitivity C-reactive protein as a key indicator in patients undergoing dialysis.

  • Biomarker Analysis
  • Inflammation Control
  • Treatment Response

The research evaluates various dosing strategies to optimize anti-inflammatory responses in patients with combined cardiovascular and kidney conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.